Burcin Ekser, Chandrashekhar A. Kubal, Jonathan A. Fridell, Asif A. Sharfuddin, Tim E. Taber, Marco A. Lacerda, Marwan S. Ghabril, John A. Powelson, William C. Goggins – 7 February 2019
Jianping Weng – 7 February 2019
Uwe Scheuermann, Minghua Zhu, Mingqing Song, John Yerxa, Qimeng Gao, Robert P. Davis, Min Zhang, William Parker, Matthew G. Hartwig, Jean Kwun, Todd V. Brennan, Jaewoo Lee, Andrew S. Barbas – 7 February 2019 – Machine preservation (MP) has emerged as a promising technology in liver transplantation, but the cellular processes occurring during MP have not been characterized. Recent studies have noted the presence of inflammatory molecules generated during MP.
Rochus A. Neeleman, Eduard J. van Beers, Edith C. Friesema, Rita Koole‐Lesuis, Willem L. van der Pol, J.H. Paul Wilson, Janneke G. Langendonk – 6 February 2019
Rochus A. Neeleman, Eduard J. van Beers, Edith C. Friesema, Rita Koole‐Lesuis, Willem L. van der Pol, J.H. Paul Wilson, Janneke G. Langendonk – 6 February 2019
Peter Jepsen, Matthew J. Grainge – 5 February 2019
Felice Ho‐Ching Tsang, Cheuk‐Ting Law, Tsz‐Ching Chloe Tang, Carol Lai‐Hung Cheng, Don Wai‐Ching Chin, Wing‐Sum Vincy Tam, Lai Wei, Carmen Chak‐Lui Wong, Irene Oi‐Lin Ng, Chun‐Ming Wong – 5 February 2019 – Hepatocellular carcinoma (HCC) cells exploit an aberrant transcriptional program to sustain their infinite growth and progression. Emerging evidence indicates that the continuous and robust transcription of oncogenes in cancer cells is often driven by super‐enhancers (SEs).
Anna Saborowski, Katharina Wolff, Steffi Spielberg, Benedikt Beer, Björn Hartleben, Zulrahman Erlangga, Diana Becker, Lukas E. Dow, Silke Marhenke, Norman Woller, Kristian Unger, Peter Schirmacher, Michael P. Manns, Jens U. Marquardt, Arndt Vogel, Michael Saborowski – 5 February 2019 – The rising incidence of cholangiocarcinoma (CCA) coupled with a low 5‐year survival rate that remains below 10% delineates the urgent need for more effective treatment strategies.
Anja Drebes, Marie de Vos, Sunita Gill, Emma Fosbury, Sue Mallett, Andy Burroughs, Banwari Agarwal, David Patch, Pratima Chowdary – 5 February 2019 – Patients with liver disease frequently develop coagulopathy, and fresh frozen plasma is traditionally used for correction of coagulopathy to manage and prevent bleeding. Prothrombin complex concentrates (PCCs) offer an attractive alternative because they are more readily available and avoid large‐volume transfusion. This retrospective, single‐center study reviewed clinical use of PCC in patients with acute/chronic liver disease.